Cargando…

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia

Detalles Bibliográficos
Autores principales:	Liu, Shuangyou, Deng, Biping, Yin, Zhichao, Pan, Jing, Lin, Yuehui, Ling, Zhuojun, Wu, Tong, Chen, Dong, Chang, Alex H., Gao, Zhiyong, Song, Yanzhi, Zhao, Yongqiang, Tong, Chunrong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005173/ https://www.ncbi.nlm.nih.gov/pubmed/32029707 http://dx.doi.org/10.1038/s41408-020-0280-y

Ejemplares similares

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

CAR‐T therapy as a consolidation in remission B‐ALL patients with poor prognosis
por: Yin, Zhichao, et al.
Publicado: (2022)

S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Pan, Jing, et al.
Publicado: (2023)

Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
por: Yang, Fan, et al.
Publicado: (2022)

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
por: Niu, Jiahua, et al.
Publicado: (2023)

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
por: Tan, Yue, et al.
Publicado: (2023)

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
por: Deng, Jingjing, et al.
Publicado: (2022)

A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL
por: Tan, Yue, et al.
Publicado: (2021)

P387: THE TREATMENT RESPONSE OF A TWO-DOSE REGIMEN OF DOSE-ADJUSTED INOTUZUMAB IN RELAPSED/REFRACTORY B-ALL
por: Liu, Shuangyou, et al.
Publicado: (2023)

A report on Lineage switch at relapse of CD19 CAR-T therapy for Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
por: Li, Lan-Zhu, et al.
Publicado: (2020)

CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Saleh, Khalil, et al.
Publicado: (2023)

CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
por: Huang, Qiusha, et al.
Publicado: (2023)

Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL
por: Deng, Biping, et al.
Publicado: (2021)

CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
por: Almaeen, Abdulrahman H., et al.
Publicado: (2023)

Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia
por: Sugita, Mayumi, et al.
Publicado: (2023)

L-Asparaginase induced thrombosis in acute lymphoblastic leukemia
por: Kulkarni, Ketan P.
Publicado: (2012)

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
por: Hassan, Mona Ali, et al.
Publicado: (2023)

Extracellular vesicle microRNAs contribute to Notch signaling pathway in T-cell acute lymphoblastic leukemia
por: Colangelo, Tommaso, et al.
Publicado: (2022)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting
por: Xu, Jieyu, et al.
Publicado: (2023)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

A case of B-cell lymphoblastic leukemia cutis flaring following CAR T-cell therapy in a patient with refractory acute lymphoblastic leukemia
por: Puri, Pranav, et al.
Publicado: (2020)

CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation
por: Xu, Qianwen, et al.
Publicado: (2022)

Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2023)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
por: Mejstríková, E., et al.
Publicado: (2017)

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: Gore, Lia, et al.
Publicado: (2018)

A functional role of Ephrin type-B receptor 6 (EPHB6) in T-cell acute lymphoblastic leukemia
por: Colucci, Mattia, et al.
Publicado: (2023)

Parental origin of monosomic chromosomes in near-haploid acute lymphoblastic leukemia
por: Lundin-Ström, Kristina B., et al.
Publicado: (2020)

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
por: Jin, Xin, et al.
Publicado: (2022)

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
por: Cao, Xuanqi, et al.
Publicado: (2022)

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory/relapsed acute B lymphocytic leukemia: Long-term follow-up results
por: Li, Zhihui, et al.
Publicado: (2023)

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
por: Feng, Jia, et al.
Publicado: (2021)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
por: Martino, Massimo, et al.
Publicado: (2021)

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
por: Xu, Xinjie, et al.
Publicado: (2021)

Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
por: Sheykhhasan, Mohsen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_678fnvij8ka0b4h1haokcjacve